Explore the latest updates to aortic stenosis (AS) management. This includes the new recommendations from the 2021 ESC/EACTS Guidelines and evidence supporting TF-TAVI as the preferred mode of intervention in patients ≥75 years of age**, as well as for additional patient groups <75 years of age1
**Based on evaluation of clinical, anatomical and procedural factors
All severe aortic stenosis (sAS) patients* should now be referred to the Heart Team for a treatment evaluation. Read the key guideline updates on the management of AS and how this may impact your daily practice.1
The challenge of long-term management of patients with sAS continues. See how valve-in-valve TAVI can provide an effective solution, and a viable alternative to reoperation in patients with a failed aortic and mitral bioprosthetic valves.4
Valve durability is a key consideration for intervention choice. Assess the follow-up data from the PARTNER 3 studies, which establish the durability of the SAPIEN valves used in TAVI, in addition to 10-year real-world data.5,6
Our monthly updates provide you the latest developments in TAVI and aortic stenosis. Read more
1Vahanian A, et al. Eur Heart J. 2021; ehab395. doi:10.1093/eurheartj/ehab395.
2Mack MJ, Leon MB, Thourani VH, et al. N Engl J Med 2019;380(18):1695-1705.
3Baron SJ, Magnuson EA, Lu M, et al. J Am Coll Cardiol 2019;74(23):2833-2842.
4Shivaraju A, Michel J, Frangieh AH, Ott I, et al. J Am Heart Assoc. 2018;7(14):e007767.
5Mack MJ, Leon MB, Smith CR, et al.Lancet 2015;385:2477-84.
6Sathananthan J, et al. Catheter Cardiovasc Interv. 2021;97(3):E431--E437.
For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable). Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.
Edwards, Edwards Lifesciences, the stylized E logo, PARTNER, PARTNER 3, SAPIEN, and SAPIEN 3 are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.